Proceeds intended to support Hims & Hers’
global expansion through organic growth and strategic acquisitions,
while also fueling deeper investment in AI, diagnostics, and
personalized treatments to scale access and meet rising demand for
high-quality, personalized care
Hims & Hers Health, Inc. (“Hims & Hers” or the
“Company”, NYSE: HIMS) today announced the pricing of its offering
of $870,000,000 aggregate principal amount of 0.00% convertible
senior notes due 2030 (the “notes”) in a private offering to
persons reasonably believed to be qualified institutional buyers
pursuant to Rule 144A under the Securities Act of 1933, as amended
(the “Securities Act”). The offering size was increased from the
previously announced offering size of $450 million aggregate
principal amount of notes. The issuance and sale of the notes are
scheduled to settle on May 13, 2025, subject to customary closing
conditions. Hims & Hers also granted the initial purchasers of
the notes an option to purchase, for settlement within a period of
13 days from, and including, the date the notes are first issued,
up to an additional $130,000,000 aggregate principal amount of
notes.
Hims & Hers intends to use proceeds from the offering for
general corporate purposes, including accelerating global expansion
through both organic growth and strategic acquisitions. Hims &
Hers has no definitive agreements for any material acquisitions at
this time. The funds will also support the technology team, led by
newly appointed CTO Mo Elshenawy, to expand the Company’s data
pipeline, develop AI tools, and advance personalized treatments to
enhance the consumer healthcare experience. In addition, a portion
of the net proceeds will be used to fund the cost of entering into
the capped call transactions described below. If the initial
purchasers exercise their option to purchase additional notes, a
portion of the additional proceeds will also be used to fund the
cost of entering into the related capped call transactions.
The notes will be senior, unsecured obligations of Hims &
Hers. The notes will not bear regular interest, and the principal
amount of the notes will not accrete. The notes will mature on May
15, 2030, unless earlier repurchased, redeemed or converted. Before
November 15, 2029, noteholders will have the right to convert their
notes only upon the occurrence of certain events. From and after
November 15, 2029, noteholders may convert their notes at any time
at their election until the close of business on the second
scheduled trading day immediately before the maturity date. Hims
& Hers will settle conversions by paying or delivering, as
applicable, cash, shares of its Class A common stock or a
combination of cash and shares of its Class A common stock, at the
Company’s option. The initial conversion rate is 14.1493 shares of
Class A common stock per $1,000 principal amount of notes, which
represents an initial conversion price of approximately $70.67 per
share of Class A common stock. The initial conversion price
represents a premium of approximately 37.5% over the last reported
sale price of $51.40 per share of the Company’s Class A common
stock on May 8, 2025. The conversion rate and conversion price will
be subject to adjustment upon the occurrence of certain events.
The notes will be redeemable, in whole or in part (subject to
certain limitations), for cash at the Company’s option at any time,
and from time to time, on or after May 19, 2028 and on or before
the 25th scheduled trading day immediately before the maturity
date, but only if the last reported sale price per share of the
Company’s Class A common stock exceeds 130% of the conversion price
for a specified period of time and certain other conditions are
satisfied. The redemption price will be equal to the principal
amount of the notes to be redeemed, plus accrued and unpaid special
and additional interest, if any, to, but excluding, the redemption
date.
If a “fundamental change” (as defined in the indenture for the
notes) occurs, then, subject to a limited exception, noteholders
may require Hims & Hers to repurchase their notes for cash. The
repurchase price will be equal to the principal amount of the notes
to be repurchased, plus accrued and unpaid special and additional
interest, if any, to, but excluding, the applicable repurchase
date.
Hims & Hers estimates that the net proceeds from the
offering will be approximately $842.7 million (or approximately
$968.8 million if the initial purchasers fully exercise their
option to purchase additional notes), after deducting the initial
purchasers’ discounts and commissions and the Company’s estimated
offering expenses. Hims & Hers intends to use approximately
$41.6 million of the net proceeds to fund the cost of entering into
the capped call transactions described below.
In connection with the pricing of the notes, Hims & Hers
entered into privately negotiated capped call transactions with one
or more of the initial purchasers or their affiliates and/or one or
more other financial institutions (the “option counterparties”).
The capped call transactions are expected generally to reduce the
potential dilution to the Company’s Class A common stock upon any
conversion of the notes and/or offset any potential cash payments
Hims & Hers is required to make in excess of the principal
amount of converted notes, as the case may be, with such reduction
and/or offset subject to a cap.
The cap price of the capped call transactions will initially be
$89.95 per share, which represents a premium of 75.0% over the last
reported sale price of the Company’s Class A common stock of $51.40
per share on May 8, 2025, and is subject to certain adjustments
under the terms of the capped call transactions.
If the initial purchasers exercise their option to purchase
additional notes, then Hims & Hers expects to enter into
additional capped call transactions with the option counterparties.
In connection with establishing their initial hedges of the capped
call transactions, the option counterparties or their respective
affiliates expect to enter into various derivative transactions
with respect to the Company’s Class A common stock and/or purchase
shares of the Company’s Class A common stock concurrently with or
shortly after the pricing of the notes. This activity could
increase (or reduce the size of any decrease in) the market price
of the Company’s Class A common stock or the notes at that
time.
In addition, the option counterparties or their respective
affiliates may modify their hedge positions by entering into or
unwinding various derivatives with respect to the Company’s Class A
common stock and/or purchasing or selling the Company’s Class A
common stock or other securities of Hims & Hers in secondary
market transactions following the pricing of the notes and prior to
the maturity of the notes (and are likely to do so (x) during any
observation period related to a conversion of notes or following
any repurchase of notes by Hims & Hers in connection with any
redemption or fundamental change or (y) following any other
repurchase of notes by the Company if the Company elects to unwind
a corresponding portion of the capped call transactions in
connection with such repurchase). This activity could also cause or
avoid an increase or decrease in the market price of the Company’s
Class A common stock or the notes, which could affect the ability
to convert the notes, and, to the extent the activity occurs during
any observation period related to a conversion of notes, it could
affect the number of shares and value of the consideration that
noteholders will receive upon conversion of the notes.
The offer and sale of the notes and any shares of Class A common
stock issuable upon conversion of the notes have not been, and will
not be, registered under the Securities Act or any other securities
laws, and the notes and any such shares cannot be offered or sold
except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act and
any other applicable securities laws. This press release does not
constitute an offer to sell, or the solicitation of an offer to
buy, the notes or any shares of Class A common stock issuable upon
conversion of the notes, nor will there be any sale of the notes or
any such shares, in any state or other jurisdiction in which such
offer, sale or solicitation would be unlawful.
About Hims & Hers
Hims & Hers is the leading health and wellness platform on a
mission to help the world feel great through the power of better
health.
Forward-Looking Statements
Except for historical information, certain statements in this
press release, including statements regarding the completion of the
offering, the expected amount and intended use of the net proceeds
and the effects of entering into the capped call transactions
described above, are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
and are subject to risks, uncertainties and assumptions about Hims
& Hers and its business, including, without limitation, risks
and uncertainties related to market conditions, the satisfaction of
the closing conditions related to the offering and risks relating
to the Company’s business. Hims & Hers may not consummate the
offering described in this press release and, if the offering is
consummated, cannot provide any assurances regarding its ability to
effectively apply the net proceeds as described above. The
forward-looking statements included in this press release speak
only as of the date of this press release, and Hims & Hers does
not undertake to update the statements included in this press
release for subsequent developments, except as may be required by
law. For a further description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
Company’s business in general, please refer to the “Risk Factors”
section in the Company’s most recently filed Quarterly Report on
Form 10-Q and its most recently filed Annual Report on Form
10-K.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250508376013/en/
Investor Relations Bill Newby Investors@forhims.com
Media Relations Abby Reisinger Press@forhims.com
Hims and Hers Health (NYSE:HIMS)
Gráfico Histórico do Ativo
De Mai 2025 até Jun 2025
Hims and Hers Health (NYSE:HIMS)
Gráfico Histórico do Ativo
De Jun 2024 até Jun 2025